Sensitization of lung cancer cells by altered dimerization of HSP27

Heat shock protein 27 (HSP27, HSPB1) induces resistance to anticancer drugs in various cancer types, including non-small cell lung cancer (NSCLC). Therefore, pharmacological inhibition of HSP27 in NSCLC may be a good strategy for anticancer therapy. Unlike other HSPs such as HSP90 and HSP70, small molecule approaches for neutralization of HSP27 are not well established because of the absence of an ATP binding domain. Previously, small molecules with altered cross linking activity of HSP27, were identified to inhibit building a large oligomer led to sensitization in combination with radiation and chemotherapeutic drugs. In this study, a chromene compound, J2 that exhibited better cross-linking activity of HSP27 than xanthone compound, SW15 which was previously identified, was yielding sensitization to NSCLC cells with high expression of HSP27 when combined with HSP90 inhibitor and standard anticancer modalities such as taxol and cisplatin. In vivo xenograft system also showed sensitization activity of J2, as well as in vitro cell viability, cell death or apoptosis detection assay. For better druggability, several quinolone compounds, an (bio) isostere of chromone and one of well-known core in many marketed medicine, was designed and synthesized by replacement of oxygen with nitrogen in 4-pyron structure of J2. However, the cross linking activity of HSP27 disappeared by quinolone compounds and the sensitizing effects on the anticancer drugs disappeared as well, suggesting oxygene moiety of 4-pyron structure of J2 may be a pharmacophore for induction of cross linking of HSP27 and sensitization to cancer cells. In conclusion, combination of chemotherapy with small molecules that induces altered cross-linking of HSP27 may be a good strategy to overcome the resistance of anticancer drugs in HSP27-over-expressing cancer cells.

[1]  Yun‐Sil Lee,et al.  Synthesis and biological effect of chrom-4-one derivatives as functional inhibitors of heat shock protein 27. , 2017, European journal of medicinal chemistry.

[2]  M. Schroeder,et al.  New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells , 2016, Oncotarget.

[3]  Yun‐Sil Lee,et al.  Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules , 2016, Oncotarget.

[4]  Junbo Hu,et al.  HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Carcinoma Cells , 2016, Oncology research.

[5]  V. Ganju,et al.  The Evolution of Therapies in Non-Small Cell Lung Cancer , 2015, Cancers.

[6]  M. Gleave,et al.  Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy , 2015, Molecular Cancer Therapeutics.

[7]  P. Solár,et al.  Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). , 2014, International journal of oncology.

[8]  Dandan Guo,et al.  Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment. , 2015, Biomaterials.

[9]  M. Katsogiannou,et al.  Heat shock protein 27 phosphorylation state is associated with cancer progression , 2014, Front. Genet..

[10]  M. Gleave,et al.  Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. , 2014, European urology.

[11]  Xu Zhang,et al.  HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). , 2014, International journal of oncology.

[12]  A. Zoubeidi,et al.  The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer , 2014, Cancers.

[13]  C. Garrido,et al.  Targeting heat shock proteins in cancer. , 2013, Cancer letters.

[14]  N. Wilson,et al.  Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target , 2012, Fibrogenesis & tissue repair.

[15]  N. Wilson,et al.  Heat shock protein 27 ( HSP 27 ) : biomarker of disease and therapeutic target , 2012 .

[16]  Renaud Seigneuric,et al.  Heat Shock Proteins as Danger Signals for Cancer Detection , 2011, Front. Oncol..

[17]  N. Gusev,et al.  Large potentials of small heat shock proteins. , 2011, Physiological reviews.

[18]  M. Schroeder,et al.  RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients , 2011, Journal of Cancer Research and Clinical Oncology.

[19]  Hae-June Lee,et al.  Altered cross-linking of HSP27 by zerumbone as a novel strategy for overcoming HSP27-mediated radioresistance. , 2011, International journal of radiation oncology, biology, physics.

[20]  M. Gleave,et al.  Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E , 2010, Oncogene.

[21]  Peiling Li,et al.  Small Interfering RNA-Mediated Silencing of Heat Shock Protein 27 (HSP27) Increases Chemosensitivity to Paclitaxel by Increasing Production of Reactive Oxygen Species in Human Ovarian Cancer Cells (HO8910) , 2009, The Journal of international medical research.

[22]  Hae-June Lee,et al.  Inhibition of heat shock protein 27-mediated resistance to DNA damaging agents by a novel PKC delta-V5 heptapeptide. , 2007, Cancer research.

[23]  Su-Jae Lee,et al.  HSP25 inhibits radiation-induced apoptosis through reduction of PKCδ-mediated ROS production , 2005, Oncogene.

[24]  A. Okamoto,et al.  Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. , 2001, Cancer letters.

[25]  Jacques Landry,et al.  Inhibition of Daxx-Mediated Apoptosis by Heat Shock Protein 27 , 2000, Molecular and Cellular Biology.